4004 news

Shein IPO, Dell Earnings, and AI Valuation Shifts

Analysis of Shein's IPO valuation versus H&M, Dell's broad-based earnings beat, and the rising bar for AI stock performance. Includes insights on fast fashion business models and pharmaceutical delivery technology.

Market Overview: Yield Shock and Tech Volatility

The trading session marked a significant shift in market dynamics, driven by geopolitical tensions in the Strait of Hormuz and a sharp rise in global bond yields. The DAX fell 1.1% to 25,970, while the Nasdaq 100 dropped 1.3%. The primary catalyst was the surge in oil and gas prices, with the TTF gas future hitting a three-year high. This inflationary pressure pushed US 10-year Treasury yields to 4.79%, a 18-month high, and Japanese 10-year yields above 3% for the first time since 1996. This yield spike has eroded the equity market's tolerance for high valuations, particularly in the tech sector.

Corporate Earnings: The New Bar for AI

Dell Technologies delivered a standout performance, with revenue up 58% to $47 billion and EPS tripling. Notably, the growth was broad-based, with classic servers and networking growing 122%, indicating a robust enterprise refresh cycle beyond just AI. In contrast, AI-centric stocks faced a harsher reality. Credo and MongoDB both beat consensus estimates but saw their shares decline significantly. This highlights a critical shift: the market no longer rewards merely beating expectations; it demands exceptional, 'fantasy' growth to justify premium multiples. MongoDB's 30% drop despite accelerating revenue growth underscores the fragility of current AI valuations.

Shein IPO and Fast Fashion Dynamics

Shein's IPO in Hong Kong resulted in a valuation of approximately $26 billion, significantly lower than its 2022 private valuation of $100 billion. Despite matching H&M in revenue, Shein is valued lower, reflecting investor skepticism toward its low-margin, high-volume model. Bernstein's analysis of the fast fashion sector reveals a clear divergence: Inditex (Zara) and Fast Retailing (Uniqlo) have delivered superior long-term returns compared to H&M and Primark. Inditex excels in profitability and working capital management, while Uniqlo offers greater expansion potential in Europe and North America. The 'Trend vs. Basics' framework suggests that brands with strong brand equity and efficient supply chains outperform those relying solely on price.

Pharma Tech: HaloSyme's Toll Station Model

HaloSyme is emerging as a critical player in the pharmaceutical delivery space, licensing enzyme technology that allows large-volume subcutaneous injections. This technology is being adopted by major pharma companies to convert infusion-based cancer drugs into injectable forms, extending patent life and improving patient compliance. With a 68% EBITDA margin, HaloSyme operates as a 'toll station' for this growing market. However, competition from Alteogen and potential patent disputes pose risks to its monopoly position. The shift from infusions to injections represents a significant structural change in drug delivery, creating opportunities for companies like West Pharmaceutical that supply the necessary components.

Conclusion

The current market environment demands a more discerning approach to equity selection. Rising yields are compressing valuations, and the bar for AI stocks has risen to require exceptional growth. In consumer sectors, business model quality is being rewarded over sheer scale. Investors should focus on companies with strong cash flow generation, clear competitive advantages, and realistic growth trajectories rather than speculative narratives.

Key insights

  1. Global bond yields are rising sharply, with US 10-year yields at 4.79% and Japanese yields breaking 3% for the first time since 1996. This is a structural shift that is beginning to impact equity valuations, particularly in growth sectors.

    Macro Economics →

    Impact: Higher yields increase the cost of capital and reduce the present value of future cash flows, pressuring high-multiple tech stocks and favoring value-oriented investments.

  2. Dell's earnings reveal a broad-based enterprise hardware refresh cycle, with classic servers and networking growing 122%. This suggests that AI capex is not the only driver of tech spending, and traditional IT infrastructure is also seeing strong demand.

    Technology →

    Impact: Companies involved in traditional server and networking infrastructure may be undervalued as the market focuses excessively on AI-specific plays.

  3. The market's reaction to Credo and MongoDB earnings indicates that beating consensus is no longer sufficient for AI stocks. Investors now expect exceptional, 'fantasy' growth rates to justify current valuations, leading to sharp declines when expectations are only modestly exceeded.

    Investment Strategy →

    Impact: AI stock valuations are becoming more fragile and sensitive to growth rate deceleration, increasing volatility and the risk of sharp corrections.

  4. Shein's IPO valuation of $26 billion, despite matching H&M in revenue, highlights the market's preference for higher-margin, brand-driven business models over low-price, high-volume strategies. Bernstein's analysis shows that Inditex and Fast Retailing have outperformed H&M and Primark over 20 years.

    Consumer Goods →

    Impact: Investors should prioritize fast fashion companies with strong brand equity, efficient supply chains, and higher margins over those relying solely on low prices.

  5. HaloSyme's enzyme technology is enabling the shift from infusion-based to injectable cancer drugs, creating a 'toll station' business model with high margins. This technology extends patent life for blockbuster drugs and improves patient compliance.

    Healthcare →

    Impact: Pharmaceutical companies are increasingly adopting injectable delivery systems, creating a growing market for HaloSyme's technology and related components like auto-injectors and specialized glass.

Action items

  • Reassess exposure to high-multiple AI stocks in light of rising bond yields and the new 'fantasy growth' bar. Consider reducing positions in companies that are not delivering exceptional growth rates.

    Impact: Mitigates the risk of sharp valuation corrections in AI stocks as the market becomes more sensitive to growth rate deceleration and rising discount rates.

  • Evaluate traditional enterprise hardware companies like Dell for potential undervaluation, given the broad-based refresh cycle indicated by their earnings. Look for companies with strong cash flow and diversified revenue streams.

    Impact: Captures upside from the enterprise IT refresh cycle, which is less speculative than pure AI plays and offers more stable growth prospects.

  • Analyze fast fashion stocks using the 'Trend vs. Basics' framework, focusing on companies with strong brand equity, efficient supply chains, and higher margins. Prioritize Inditex and Fast Retailing over H&M and Primark.

    Impact: Aligns investment strategy with long-term performance trends in the fast fashion sector, favoring companies with sustainable competitive advantages.

  • Investigate the pharmaceutical delivery technology space, focusing on companies like HaloSyme that license enzyme technology for injectable drugs. Assess the competitive landscape and potential risks from patent disputes.

    Impact: Identifies opportunities in a growing niche with high margins and structural tailwinds from the shift from infusions to injections in cancer treatment.

  • Monitor global bond yields and their impact on equity valuations, particularly in growth sectors. Consider hedging strategies or shifting to value-oriented investments to mitigate the risk of rising yields.

    Impact: Protects portfolio value from the negative impact of rising yields on high-multiple stocks and positions the portfolio for a more defensive market environment.

Quotes

“Der Aktienmarkt habe diese Renditebewegung. das ganze Jahr bislang ignorieren können. Höhere Renditen seien für Aktien so lange egal, bis sie es plötzlich nicht mehr sind.”
“Bei KI-Werten wird nicht mehr der Konsens geschlagen, sondern die Fantasie.”
“In der Krebstherapie findet gerade eine spannende Umstellung statt. Medikamente, die bislang über Stunden als Infusion verabreicht wurden, gibt es zunehmend auch als Spritze.”